Randy Polonsky Named CFO at Biocartis

Biocartis N.V. has welcomed a new member into its executive leadership circle, having appointed Randy Polonsky as chief financial officer. This key hire occurs as Biocartis works to expand its footprint in the oncology diagnostics sector.

Polonsky brings a wealth of experience in financial planning and analysis, corporate development, operational excellence, and leadership across both public and private equity global companies. Most recently, he was vice president of Financial Planning and Analysis and Corporate Development at Talis Biomedical, where he established a strategy to enhance financial performance while preparing to commercialize a new point-of-care diagnostic system. Before Talis, Polonsky worked at Vyaire Medical and CDW, where he held progressively senior roles in finance.

“Randy’s expertise will be instrumental as we accelerate growth and become profitable,” Biocartis CEO Roger Moody said. “His strategic vision will help align our business and financial objectives, helping us complete Biocartis’ transformation.”

With its proprietary Idylla Platform, Biocartis aspires to enable personalized medicine for patients worldwide through universal access to molecular testing, by making such testing actionable, easy, fast and suitable for any lab. The Idylla Platform is a fully automated sample-to-result, real-time PCR (polymerase chain reaction)-based system designed to offer in-house molecular biomarker testing in three hours, allowing fast and optimal treatment selection and disease progress monitoring. ​Idylla’s molecular diagnostic test menu addresses key unmet clinical needs with a focus on oncology. Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid, brain, blood and liver cancer.